Biogen: Muscular Atrophy trials

The registry lists 14 Muscular Atrophy studies with Biogen as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 4Phase 2 3Phase 3 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyCompletedNCT04089566Phase 3Results posted
• A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational StudiesCompletedNCT02594124Phase 3Results posted
• A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).TerminatedNCT02462759Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)CompletedNCT02292537Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular AtrophyTerminatedNCT02193074Phase 3Results posted
• A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)CompletedNCT01839656Phase 2Results posted
• An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular AtrophyCompletedNCT01703988Phase 1/2Results posted
• Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular AtrophyCompletedNCT05354414Not applicable
• A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular DisordersCompletedNCT05109637Not applicable
• Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium InjectionCompletedNCT04419233
• Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)No longer availableNCT02865109
• An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)CompletedNCT02052791Phase 1
• An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)CompletedNCT01780246Phase 1
• An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)CompletedNCT01494701Phase 1